Scholar Rock
620 Memorial Drive, 2nd Floor
Cambridge
Massachusetts
02139
United States
Tel: 857-259-3860
Fax: 866-493-4935
Website: http://www.scholarrock.com/
120 articles with Scholar Rock
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/15/2023
Scholar Rock today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 15,000 shares of common stock.
-
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
3/7/2023
Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2022.
-
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
3/1/2023
Scholar Rock today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab.
-
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference
2/27/2023
Scholar Rock today announced that management will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET.
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 17, 2023
2/17/2023
Scholar Rock announced that the Company granted inducement equity awards covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 255,000 shares of common stock and inducement restricted stock units, covering an aggregate of 30,000 shares of its common stock.
-
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer
2/6/2023
Scholar Rock today announced the appointment of Tracey M. Sacco as Chief Commercial Officer.
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
1/9/2023
Scholar Rock today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023.
-
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Scholar Rock today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET).
-
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/15/2022
Scholar Rock today announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in November 2022.
-
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
11/14/2022
Scholar Rock today reported financial results and corporate updates for the third quarter ended September 30, 2022.
-
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
11/10/2022
Scholar Rock today announced early data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation being developed with the aim of overcoming resistance to checkpoint therapy in patients with advanced cancer.
-
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
11/9/2022
Scholar Rock today announced the appointment of Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer.
-
Scholar Rock to Participate in Upcoming Investor Conferences
11/8/2022
Scholar Rock today announced that management will participate in the following upcoming investor conferences.
-
New data from Scholar Rock’s Phase II TOPAZ trial showed its investigational antibody apitegromab improves quality of life in types 2 and 3 spinal muscular atrophy patients.
-
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
10/22/2022
Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months These data indicate the potential for sustained improvement in quality-of-life measures for patients with symptomatic SMA and offer further evidence of possible durable effects of apitegromab
-
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
10/4/2022
Scholar Rock announced that it will be presenting additional data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24-months of treatment with apitegromab, an investigational selective inhibitor of the activation of myostatin for spinal muscular atrophy.
-
Seven biopharma companies are under new leadership. This week's Movers & Shakers highlights these new chief executive officers who aim to guide their companies into the future.
-
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 22, 2022
9/22/2022
Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in September 2022.
-
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
9/20/2022
Scholar Rock today announced that its Board of Directors appointed Jay Backstrom, M.D., M.P.H., as Chief Executive Officer-Elect, effective September 20, 2022.
-
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
9/16/2022
Scholar Rock today announced two upcoming presentations.